- Home
- PROF vs OBIO Comparison
PROF vs OBIO Comparison
Compare PROF & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- OBIO
- Stock Information
- Founded
- PROF N/A
- OBIO 2017
- Country
- PROF Canada
- OBIO United States
- Employees
- PROF N/A
- OBIO N/A
- Industry
- PROF Medical/Dental Instruments
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- PROF Health Care
- OBIO Health Care
- Exchange
- PROF Nasdaq
- OBIO Nasdaq
- Market Cap
- PROF 134.3M
- OBIO 147.8M
- IPO Year
- PROF N/A
- OBIO N/A
- Fundamental
- Price
- PROF $4.09
- OBIO $2.60
- Analyst Decision
- PROF Strong Buy
- OBIO Strong Buy
- Analyst Count
- PROF 1
- OBIO 4
- Target Price
- PROF $11.00
- OBIO $14.00
- AVG Volume (30 Days)
- PROF 181.3K
- OBIO 261.5K
- Earning Date
- PROF 11-06-2025
- OBIO 11-11-2025
- Dividend Yield
- PROF N/A
- OBIO N/A
- EPS Growth
- PROF N/A
- OBIO N/A
- EPS
- PROF N/A
- OBIO N/A
- Revenue
- PROF $11,840,000.00
- OBIO $2,944,000.00
- Revenue This Year
- PROF $60.07
- OBIO $19.83
- Revenue Next Year
- PROF $121.80
- OBIO $12.53
- P/E Ratio
- PROF N/A
- OBIO N/A
- Revenue Growth
- PROF 59.81
- OBIO 41.61
- 52 Week Low
- PROF $3.76
- OBIO $2.37
- 52 Week High
- PROF $9.17
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- PROF 35.14
- OBIO 44.18
- Support Level
- PROF $3.76
- OBIO $2.57
- Resistance Level
- PROF $4.69
- OBIO $2.79
- Average True Range (ATR)
- PROF 0.19
- OBIO 0.15
- MACD
- PROF -0.00
- OBIO -0.00
- Stochastic Oscillator
- PROF 33.67
- OBIO 10.50
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.